← Back to Search


Open label BSS for COVID-19 (SABER-C Trial)

Phase 4
Waitlist Available
Led By Bruce Yacyshyn, MD
Research Sponsored by University of Cincinnati
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up day 3 - or 48 hours after starting bss
Awards & highlights


This trial will investigate whether or not bismuth subsalicylate can help treat or even prevent the novel coronavirus.

Eligible Conditions
  • COVID-19
  • Diarrhea
  • Coronavirus


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 3 - or 48 hours after starting bss
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 3 - or 48 hours after starting bss for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Measure of Daily Stool Frequency for Patients With COVID Treated With Bismuth
Secondary outcome measures
Salivary SARS-CoV2 Day 3 Status Using Reverse-transcription Loop-mediated Isothermal Amplification (RT-LAMP)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Open label BSSExperimental Treatment1 Intervention
All patients will be assigned to the treatment group for the first 10 patients treated with open label BSS.
Group II: Randomized BSS or PlaceboPlacebo Group2 Interventions
The Subsequent 50 patients will be randomized to either placebo or BSS. The patients will be assigned by envelope containing a symbol for either active drug or placebo (or other suitable randomization event) by a member of the research team not directly involved in the clinical trial.
First Studied
Drug Approval Stage
How many patients have taken this drug
Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable
Completed Phase 4

Find a Location

Who is running the clinical trial?

University of CincinnatiLead Sponsor
431 Previous Clinical Trials
634,486 Total Patients Enrolled
1 Trials studying COVID-19
32 Patients Enrolled for COVID-19
Procter and GambleIndustry Sponsor
146 Previous Clinical Trials
76,520 Total Patients Enrolled
University of LouisvilleLead Sponsor
340 Previous Clinical Trials
77,310 Total Patients Enrolled
1 Trials studying COVID-19
250 Patients Enrolled for COVID-19
~13 spots leftby Jul 2025